The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
Abstract
Objective Peripheral infusions of glucagon-like peptide-1 (GLP-1) in humans have been shown to inhibit gastrointestinal motility and decrease hunger and energy intake. However, these investigations used supraphysiological doses. The objective of this study was to investigate the effects of a GLP-1 infusion in a physiological dose on appetite sensations, energy intake, gastric emptying, energy and substrate metabolism. Methods Eighteen obese men participated in the placebo-controlled, randomized, single-blinded, cross-over study with infusion of GLP-1 or saline. Resting metabolic rate (RMR) and substrate oxidations were measured by ventilated hood before and after an energy-fixed breakfast. Gastric emptying was measured using paracetamol as a marker. Visual analogue scales were used to assess appetite sensations, thirst and comfort throughout the experiment and palatability of the test meals. Blood was sampled for analysis of hormones (GLP-1, GLP-2, glucose-dependent insulinotropic polypeptide (GIP), insulin, glucagon), and substrates (glucose, lactate, non-esterified fatty acids (NEFA), triacylglycerol (TAG)). Ad libitum energy intake at lunch was registered. Results Following the breakfast, GLP-1 infusion suppressed ratings of hunger and prospective food consumption (P Conclusion It is concluded that GLP-1 in physiological concentrations powerfully reduces the rate of entry of nutrients into the circulation by a reduction of gastric emptying rate in obese subjects. The effec…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 has been shown to inhibit glucagon secretion and slow gastric emptying.5, 6”
Citations
Cites
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801083 · Cited by 2,238
Self-citationA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citationAnalysis of Longitudinal Data.
Have, T. R. T., Diggle, P. J., Liang, K.-Y., & Zeger, S. L. (1995) · Journal of the American Statistical Association · doi:10.2307/2291352 · Cited by 1,171
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationTriglycerides Determination after Enzymatic Hydrolysis
Wahlefeld, A. W. (1974) · Methods of Enzymatic Analysis · doi:10.1016/b978-0-12-091304-6.50036-7 · Cited by 822
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Research works printed but not linked: 1
- Noll F . L-(+)-Lactate. Determination with LDH, GPT and NAD. In: Bergmayer HU (ed).Methods of enzymatic analysis, 2nd ed. Academic Press: New York 1974.
Cited by
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Self-citationIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
“In contrast, exogenous GLP-1 reduces appetite, increases satiety, and reduces food intake,(53) perhaps even at physiological concentrations.(127) This, together with the reduced secretion of GLP-1 in obese subjects, suggests a significant role of GLP-1 in the pathogenesis of obesity.”
BackgroundKim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
The role of short chain fatty acids in appetite regulation and energy homeostasis
Byrne, C. S., Chambers, E. S., Morrison, D. J., & Frost, G. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.84 · Cited by 707
The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
“Glucagon-like peptide 1 (GLP1) analogues (exenatide and liraglutide) are novel therapeutic options for T2D, acting as incretin mimetics that share similar glucoregu-latory properties with the gut peptide hormone GLP1, including glucose-dependent enhancement of insulin secretion (228).”
Metadata
- Authors
- Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A.
- Corresponding author
- Flint, A
- Venue
- International Journal of Obesity
- Published
- 2001-06
- Volume
- 25
- Issue
- 6
- Pages
- 781-792
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2084142744
- Cited by
- 384
- References
- 51
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 30 · 2023: 8 · 2022: 9 · 2021: 10 · 2020: 11 · 2019: 6 · 2018: 15 · 2017: 9 · 2016: 20 · 2015: 25 · 2014: 21 · 2013: 22 · 2012: 20
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- glucagon-like peptide-1, obesity, appetite, gastric emptying, energy intake, resting metabolic rate, substrate oxidation, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-2, free fatty acids, triglycerides, insulin, glucagon, weight loss
- MeSH terms
- Adult, Appetite, Basal Metabolism, Energy Metabolism, Gastric Emptying, Glucagon, Humans, Kinetics, Male, Obesity, Oxidation-Reduction, Peptide Fragments, Protein Precursors, Body Mass Index, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. https://app.cochat.ai/papers/10.1038/sj.ijo.0801627
- The paper
- Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001). The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity. https://doi.org/10.1038/sj.ijo.0801627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.